Going Founder Mode on Cancer: How GitLab's CEO Used AI and Genomics to Fight Osteosarcoma
GitLab CEO Sid Sijbrandij applied his engineering mindset to his own osteosarcoma diagnosis, assembling a team that used single-cell sequencing, AI-guided therapy selection, and experimental treatments to achieve remission after standard oncology protocols failed.
When GitLab CEO Sid Sijbrandij's osteosarcoma recurred in 2024 after surgery, radiation, and aggressive chemotherapy, he found himself outside the scope of conventional clinical trials. Rather than accept the prognosis, he applied what might be called 'founder mode' to his own cancer — assembling a team including Jacob Stern from 10x Genomics and pursuing an information-maximalist approach that generated over 1,000 pages of health documentation in 2025.
His strategy rested on three principles: maximal diagnostics (every available test, frequently), personalized treatments (developing 10+ individualized therapies), and parallel interventions (testing multiple hypotheses simultaneously rather than sequentially). Single-cell sequencing revealed fibroblast markers in his tumor, leading to experimental FAP-targeting radioligand therapy in Germany.
The results were remarkable. The radioligand therapy shrunk his cancer sufficiently for surgical resection, and post-surgery analysis showed T-cell infiltration had increased from 19% to 89%, indicating successful immune activation. Sijbrandij's cancer is now in remission, and he continues aggressive monitoring with personalized neoantigen vaccine therapy as maintenance.
The essay explores how Sijbrandij's case exposes gaps in current oncology: difficulty accessing tissue samples, limited genomic sequencing integration, expensive drug development, and regulatory bottlenecks. His approach — while not scalable to most patients today — points toward a future where emerging technologies like personalized neoantigen vaccines, CAR-T therapy, and AI-guided treatment selection could make this level of precision oncology more accessible.